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Abstract
Background: Studies reported contradictory results for the prognostic significance of a pathological fracture in
osteosarcoma patients. The aim of this study is to report the outcomes for a cohort of patients with osteosarcoma
who presented with and without pathological fractures and to identify the prognostic importance of pathological
fracture in predicting outcomes and influences on survival.
Methods: Data of patients with osteosarcoma were retrospectively reviewed. Between March 1992 and June
2014, a total of 268 patients with osteosarcoma were included in this analysis, of whom 34 (12.7%) with
fractures at diagnosis or sustained after chemotherapy and 234 (87.3%) without fracture. All patients were
treated with approaches that integrated chemotherapy and surgical resections to maximal extent of all sites
whenever feasible. The association between potential prognostic factors and survival for these patients were
analyzed and compared.
Results: No significant difference was observed in overall survival, progression free survival, and disease free survival
between osteosarcoma patients with pathological fractures and without fracture. The patients without fracture had a 5-
year survival of 50% and 10-year survival of 21%, in contrast to 37% (5-year) and 22% (10-year) in patients with fractures.
Lung metastasis was the significant predictor for the presence of fractures. Advanced stage (III) of tumor, lung
metastasis, poor response to chemotherapy, and local recurrence were associated increased risk for death in all
osteosarcoma patients.
Conclusion: Pathological fracture is not a predictor of worse survival in this study. Further studies with matched
cases are needed to confirm our observations.
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Background
Pathological fracture in osteosarcoma, with an incidence
from 5% to 12%, can be the presenting feature at diagno-
sis of or occur during treatment [1]. Studies reported
that metastases occur in 10–20% of osteosarcoma
patients at the time of diagnosis [2], and lung and bone
are the most common sites [2, 3]. The current multidis-
ciplinary treatment program for osteosarcoma, typically
composed of surgical management, pre- and post-operative
chemotherapy, has provided about a cure rate of for pa-
tients without clinically evident metastasis at presentation
[4, 5]. However, for the osteosarcoma patients present with
metastatic disease, the reported 5-year survival rates ranged
from 10% to 50% [3]. Significant predictors of survival for
osteosarcoma patients include metastases, anatomic site,
histological response to chemotherapy, serum levels of alka-
line phosphatase, and lactate dehydrogenase [5].
Pathological fractures in osteosarcoma patients are
considered to induce hematomas, increase the risk of
unexpected micro-metastasis [6, 7] and has been linked
to the higher mortality rates as a result of metastatic
cancer progression [1]. The management of osteosar-
coma is complicated by pathological fracture; however,
studies have reported contradictory implications of
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pathological fracture, in which similar survival [8, 9] and
worse survival [10–12] were indicated. Some recent
studies reported that a pathological fracture has no
significant prognostic value in patients with high-grade
extremity osteosarcoma [13, 14] and is a poor predictor
for local recurrence despite an association with in-
creased mortality [15]. Nevertheless, Scully et al. con-
cluded that pathological fractures in patients previously
treated for osteosarcoma can be used as a risk factor for
local recurrence [11]. Because of the relative rarity of
osteosarcoma patients, most studies examining patho-
logical fractures in osteosarcoma patients [9, 13–18]
included patients might be matched for some criteria
(e.g. cancer stage, localized disease), but varied widely in
other important parameters (such as chemotherapy regi-
mens, metastasis, age, lesion site, surgical extent, limb
amputation or salvage, etc.). Thus, comparisons between
studies have been difficult and the usefulness of patho-
logical fracture as a prognostic indicator of survival out-
come or recurrence remains controversial. According to
a previous study investigating the effects of manipulative
therapy on the prognosis for osteosarcoma’s patients in
our institution [19], surgery followed by neoadjuvant
chemotherapy could boost overall survival rate to 92%,
in contrast to 58% of patients received manipulative ther-
apy and they were associated with significantly higher
rates of metastasis and poorer prognosis (p < 0.05). As we
have identified manipulative therapy a risk factor of sur-
vival rate, this study was therefore undertaken to examine
whether a pathologic fracture in patients with osteosar-
coma has prognostic importance in predicting outcomes
and influences on survival.
Methods
Screening of eligible patients
We retrospectively reviewed the medical charts of pa-
tients with osteosarcoma who were treated and followed
up at Taipei General Veterans Hospital between March
1992 and June 2010. This study was conducted following
the approval of Institutional Review Board of Ditmanson
Medical Foundation Chia-Yi Christian Hospital (Taiwan)
and the obtaining of patients’ informed consent. Data
were retrieved from the medical charts, including age at
diagnosis, gender, histology of osteosarcoma, anatomic
location of tumor and related fracture, categorization of
fracture, the presence of metastasis and time, details of
therapeutic regimens, surgical therapy, responses to
chemotherapy, and dates of the last follow-up or death.
Patients were included in this study based on (1) presen-
tation of osteosarcoma of the femur, humerus, tibia, fib-
ula or other areas; (2) no previous pathological fracture.
Patients excluded were those with (1) previous diagnosis
of pathological fracture; (2) other cancer history or treat-
ment, and (3) lost to follow-up or incomplete.
Diagnosis and follow-ups
All the patients with pathologically confirmed diagnosis
of osteosarcoma underwent computer tomography (CT)
scan, magnetic resonance imaging (MRI), and/or sonog-
raphy. The presence of a pathological fracture in these
patients was also obtained from the medical charts of
the whole course of treatment. Tumors were staged ac-
cording to Enneking’s Musculoskeletal Tumor Society sys-
tem [20]. Tumor sizes were calculated using the formula:
0.52 × [width (mm) × height (mm) × length (mm)] [21],
with the measurements determined from MRI. Tissue
diagnoses were obtained by needle biopsy for all the cases.
The follow-up protocols and imaging schedules were
consistent during the period. CT scan of the chest was
performed before surgery, every three months in the first
two years post-operatively, every six months during the
third to fifth years, and then annually thereafter. Local
recurrences over the primary tumor location were moni-
tored with roentgenographies, and either MRI and/or
sonography on the same schedule. The imaging studies
were reviewed and interpreted by certified radiologists of
this institution. Both groups of patients with a patho-
logical fracture and without fracture were observed in
the outpatient clinics following discharge until either
relapse or death was reported. Physical examination,
radiograph, CT scan, bone scan, and MRI were included
in follow-up assessments.
Clinical management and treatment strategies
The patients were treated according the most appropri-
ate therapeutic regimen for each patient at the time of
the treatment, involving chemotherapy and surgical
interventions. The pre-operative neoadjuvant chemo-
therapy regimen was standardized after 2003, including
12 mg/m2 methotrexate, 37.5 mg/m2/day adriamycin,
3.0 mg/m2/day ifosfamide and 60 mg/m2/day cisplatin
for a minimum of 2 cycles [22]. Adjuvant chemotherapy
following surgery was provided according to the guidelines
of National Comprehensive Cancer Network (NCCN) for
bone cancer. The response to neoadjuvant chemotherapy
was evaluated by pathological estimation of the resected
specimen according to the method defined by Huvos et al.
[23]. A good response to chemotherapy was defined to
achieve more than 90% of tumor necrosis.
After chemotherapy and reassessment, all patients
received the definite tumor surgery based on their
responses to chemotherapy, location and extension of
tumor, and patient age, to achieve wide surgical margins
as much as possible. Limb-salvage and limb-sacrificing
procedures were considered according to chemothera-
peutic responses or based on patient preference. All the
pathological fractures were managed according to guide-
lines at that time and each patient needs [24], including
temporally external fixation for femoral diaphysis and
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followed by limb salvage surgery. Distal femoral and
proximal tibial metaphysis were stabilized with long leg
cast through the whole course of preoperative treatment.
No fixation device was applied for proximal femoral
metaphysis. Ambulation with crutches was allowed for
these patients whenever necessary.
Statistical analysis
Patients were categorized into two groups according to
the presence and absence of a pathological fracture. All
data were analyzed using the SPSS software, version 16.0
(SPSS Inc., Chicago, IL, USA) and expressed as mean ±
standard deviation (SD) for numeral data or frequencies
for categorical data. A p-value of less than 0.05 was con-
sidered to indicate a statistically significant difference.
The differences in the demographic data and the clinical
characteristics between the two groups were evaluated
by Pearson chi-squared tests. Comparisons of the vari-
ables such as age, gender, tumor stage and response to
chemotherapy between the groups were accessed by
independent Student’s t-test.
Cox regression model was used to conduct multivari-
ate analysis. Variables were evaluated to determine their
prognostic values in relations to overall survival (OS),
progression free survival (PFS) and disease free survival
(DFS). OS was calculated from the time of diagnosis
until the last follow-up or death. PFS was calculated
from the time of diagnosis until the first documentation
of progression (metastasis) or recurrence, last follow-up
or death. DFS was defined as the period of no evidence
of disease survival following curative therapy (chemo-
therapy and surgery) until the last follow-up.
Results
Characteristics and outcomes
From March 1992 to June 2014, a total of 268 patients
with osteosarcoma had received a complete treatment
protocol without any improper intervention, including
12.7% patients (n = 34) with sustained pathological
fractures related to osteosarcoma and 87.3% patients
(n = 234) without fracture. Of the patients with frac-
tures, 65% had a fracture at diagnosis and the others
developed a fracture after biopsy or chemotherapy (data
not shown). As summarized in Table 1, although the over-
all ratio of males to females was 1.48 (n = 160/108),
female patients had significantly higher frequency of
fractures (p = 0.030). Mean ages at diagnosis were
22.8 ± 15.2 and 23.5 ± 19.1 years, and no difference in
the categorized age groups. The majority of patients pre-
sented with Enneking stage-IIB disease, including 86.3%
(n = 202) patients with fractures and 79.4% (n = 29)
patients without fractures. No significant difference was
observed in the distribution of tumor stages (p = 0.112)
and mean sizes of tumor (p = 0.907) between patients with
and without fractures. Femur, tibia, and humerus
accounted for more than 70% of tumors. The patients
with fractures had higher percentages of tumors pre-
sented at femur and humerus, but a lower frequency
occurred at tibia when compared with those without
fracture. A significant higher percentage of lung metas-
tasis, either at initial presentation or occurred during
follow-up, was found in the patients with a fracture
(50.0% vs. 32.1%; p = 0.039). No significant difference
was detected for the rates of local recurrence or average
duration to recurrence following treatment.
Similar outcomes in terms of survival were noted,
approximately 46% were freed of disease while 36%
eventually died as a result of tumor and 16% is still
alive with the disease. Furthermore, no significant
difference was observed in the responses to chemo-
therapy according to the degree of tissue necrosis
rates and the follow-up duration [68.0 ± 52.1 (median
52.0; range 0.7–277.7) and 65.2 ± 57.7 (median 45.0;
range 1.0–200.4) months, p = 0.362]. Survival and dis-
ease status (no evidence of disease, alive with disease,
and died of disease), OS (p = 0.338), PFS (p = 0.841),
and DFS (p = 0.667) all revealed no statistically signifi-
cant difference.
Analyses of prognostic factors
In Table 2, univariate analysis showed that only the pres-
ence of lung metastasis was a significant predictor of
fracture (OR = 2.12; p = 0.043), but gender, poor necrosis
rate (<90%), and local recurrence were not significantly
correlated with the presence of fractures. Table 3 shows
the analysis of variables in predicting death in osteosar-
coma patients. Tumor stage III (OR = 12.00; p = 0.043),
poor necrosis (OR = 2.11; p = 0.048), lung metastasis
(OR = 3.32; p = 0.000), and local recurrence (OR = 1.81;
p = 0.046) were significant predictors of death in patients
with osteosarcoma. However, pathological fracture, age,
gender, tumor stage IIB, and tumor location were not sig-
nificantly associated with the survival for these patients.
All these findings suggest that lung metastasis appears
to be a predictor of pathological fractures and a prog-
nostic factor of survival in osteosarcoma patients with
fractures. In contrast, additional logistic regression ana-
lysis demonstrated that pathological fracture is not a
significant predictor of lung metastasis (OR = 0.947,
95%CI, 0.449–1.997; p = 0.886). In addition to lung
metastasis, necrosis rate in response to chemotherapy
and local recurrence were significantly associated with
inferior survival in all osteosarcoma patients.
Survival outcomes
The probabilities of OS and PFS by months of the whole
groups are shown in Fig. 1. No significant difference was
observed between the osteosarcoma patients with fractures
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Table 1 Demographics, disease-related characteristics and outcomes of non-fracture and fracture groups in 268 patients with
osteosarcoma
Characteristics Non- Fracture
N = 234 (87.3%)
Fracture
N = 34 (12.7%)
p*
N %, or mean ± SD N %, or mean ± SD
Gender
Males 141 60.3 19 55.9 0.030
Females 93 39.7 15 44.1
Age, years
Mean 22.8 ± 15.2 23.5 ± 19.1 0.836
≤ 10 24 10.3 5 14.7 0.626
10–20 124 53.0 19 55.9
> 20 84 35.9 10 29.4
Stage of tumor a
IB 4 3.2 0 0 0.112
IIB 202 86.3 27 79.4
III 28 22.6 7 38.9
Tumor size, mm2 148 363.7 ± 641.1 16 389.4 ± 845.9 0.907
Tumor location
Femur 94 40.2 18 52.9 0.020
Tibia 49 20.9 3 8.8
Humerus 16 6.8 10 29.4
Fibula 6 2.6 1 2.9
Others b 21 9.0 2 5.9
Not Specified 48 20.5 0 0.0
Lung metastasis c
No 159 67.9 17 50.0 0.039
Yes 75 32.1 17 50.0
Necrosis rate, %
< 90% (poor) 41 31.1 13 44.8 0.351
≥ 90% (good) 65 49.2 12 41.4
No preoperative C/T d 26 19.7 4 13.8
Local recurrence
No 183 78.2 26 76.5 0.820
Yes 51 21.8 8 23.5
Status until last follow up
No evidence of disease 108 46.4 16 47.1 0.904
Alive with disease 35 15.1 6 17.6
Died of disease 89 38.4 12 35.3
Duration to recurrence, months 41 23.1 ± 20.9 5 12.8 ± 9.4 0.084
Follow up duration, months 234 68.0 ± 52.1 34 65.2 ± 57.7 0.362
Overall survival, months 234 65.7 ± 48.9 34 56.4 ± 52.3 0.338
Progression free survival, months 134 67.9 ± 52.0 20 65.2 ± 57.7 0.841
Disease-free survival, months 108 87.1 ± 48.1 16 80.8 ± 55.1 0.667
aEnneking stage
bOthers included radius, pelvis, hip, sinonasal, skull, spine, neck, and scapula
c Metastasis at diagnosis or developed during follow-up
dC/T: chemotherapy
*Comparisons were based on the independent student t-test and Pearson chi square test
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and without fracture (p = 0.962 for OS, p = 0.664 for PFS).
The 5-year and 10-year survival rates were 50% and 21%
for patients without fracture compared to 37% and 22% in
patients with a pathological fracture. The difference was
not statistically significant (p = 0.312) (Fig. 2). For non-
metastatic patients, the rates were 56% and 23% for those
without fracture vs. 47% and 29% for those with fractures;
and for metastatic patients, the rates were 36% and 16%
(patients without fracture) vs. 24% and 12% (patients with
fractures) (Fig. 2a & b; p = 0.004). Similarly, PFS rates did
not significantly differ between the two whole groups, but
varied greatly depending on the presence of lung metasta-
sis, with no PFS survivor in the group of patients with
fractures at the 5th year and significantly less 5-year survi-
vors with lung metastases in patients with fractures (Fig. 2c;
p = 0.000).
Discussion
The present study examined the prognostic importance
of pathologic fractures for osteosarcoma patients. The
patients of both groups were comparable in age, tumor
stage and size, local recurrence, and necrosis rate. Our
results revealed no significant difference in the OS, PFS,
5-year, and 10-year survival between the two groups.
The findings are similar to previous studies indicating
that pathological fractures in osteosarcoma do not ad-
versely affect survival [9, 13], unless the presence of lung
metastasis. Furthermore, our study also supports the
contention that proper evaluation of preoperative im-
aging, following by appropriate chemotherapy regimens,
and surgical approaches can result in no difference in
tumor necrosis rates or the risk of local recurrence
between patients with fractures and without fracture,
suggesting that an effective multidisciplinary team can
provide consistent outcomes in spite of the management
of fractured patients is more difficult.
In this study, lung metastasis was a significant pre-
dictor for fracture and one of significant risk factors for
death for the entire study population. Comparing to the
incidence rates of lung metastasis in osteosarcoma
patients with fractures in previous studies, 19.3% [17] or
23% [11], this study clearly demonstrated a much higher
proportion of patients with fractures had lung metastases,
with 50% in patients with fractures and 32% in those with-
out fracture. Although a pathological fracture per se was
not a significant predictor for survival, lung metastases
and fractures could promote the progression of osteosar-
coma and led to an inferior survival in fractured patients.
Metastasis at diagnosis is the only widely accepted prog-
nostic factor [2]. The contemporary treatment regimens
can result in up to 70% survival for patients with localized
osteosarcoma of the extremity. But the survival estimates
for patients with metastatic disease were much worse, ran-
ging from 8.3% for 5-year [25], 23% for 5-year [26], 30%
for 4-year [27], 53.3% for 5-year [28], to 55% for 2-year
[29]. However, these studies varied widely in many
variables, making comparisons impossible. The long-term
survival data were neither reported.
Local recurrence can be a result of poor response to
chemotherapy or inadequate surgical margins [30, 31].
The rates of local recurrence following osteosarcoma
surgery generally ranged 4–10% [32–34]. In our study,
the rates were relatively higher (21.8% and 23.5%), but
lower than a more recent study reporting the rates in
patients with adequate (30.5%) and inadequate (38%)
surgical margins, and in which, 15% patients had patho-
logical fractures [35]. Consistent with previous observa-
tions [32, 35, 36], local recurrence was correlated with
poor prognosis in terms of survival in the present study.
To determine the impact of surgical margin on the
development of local recurrence, further investigation
remains necessary.
Tumor size has been considered as an important risk
factor for osteosarcoma patients [15] and a potential
Table 2 Odds ratios of variables associated the presence of
pathological fractures in patients with osteosarcoma, by univariate
logistic regression
Factor Odds ratio 95% CI p (chi-square)
Gender (female vs. male) 1.20 0.58–2.47 0.627
Poor necrosis rate (<90%) 1.72 0.72–4.13 0.227
Lung metastasis 2.12 1.03–4.38 0.043
Local recurrence 1.10 0.47–2.59 0.820
CI: confidential interval
Table 3 Univariate logistic regression to identify risk factors for
the prediction of death in all patients with osteosarcoma (total
n = 268)
Variable OR 95% CI p
Fracture (reference: no fracture) 0.88 0.41–1.86 0.731
Age group (reference: ≤ 10)
10–20 1.52 0.63–3.67 0.355
>20 2.03 0.82–5.05 0.127
Gender (reference: male) 0.80 0.48–1.34 0.420
Tumor stage (reference: IB)
IIB 1.68 0.17–16.75 0.658
III 12.00 1.08–133.61 0.043
Tumor location (reference: fibula)
Femur 0.96 0.21–4.51 0.963
Tibia 0.52 0.12–2.96 0.524
Humerus 0.31 0.07–2.31 0.306
Necrosis rate < 90% (reference: ≥ 90%) 2.11 1.01–4.44 0.048
Lung metastasis (reference: no) 3.32 1.96–5.62 0.000
Local recurrence (reference: no) 1.81 1.01–3.25 0.046
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confounding factor associated with poor prognosis for
those with fractures [13, 37]. Increased tumor volume
might result in poor response to chemotherapy [38];
however, other studies did not find an influence of
tumor size [11]. In our series, tumor size was not signifi-
cantly correlated with OS for all patients, patients with
or without fractures (data not shown). Moreover, we
found that fractured female patients had a better survival
than male counterparts in exploratory subgroup ana-
lyses, which has never been reported. We also analyzed
the 10-year survival rates that were generally lack in
most studies. Although the data of this study was
Fig. 1 Cox regression multivariate analysis of comparing survival between osteosarcoma patients with pathological fractures and those without
fracture, with simultaneous adjustment for tumor stage, metastasis, tumor size, necrosis rate, and age. No significant difference was found for
a Overall survival (p = 0.962) and b Progression free survival (p = 0.664)
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relevant to both pediatric and adult patients, the sample
size remained small so that the exploratory analyses for
subgroups were limited.
Conclusions
A pathological fracture in patients with osteosarcoma
did not increase the risk of death. No significant differ-
ence was observed in OS, PFS, or DFS between osteosar-
coma patients with fractures and without fracture. Lung
metastasis at diagnosis was a significant predictor for
the presence of a pathological fracture. Advanced stage
(III) of tumor, lung metastasis, poor response to chemo-
therapy, and local recurrence were associated an increased
risk for death in all patients with osteosarcoma. Further
confirmation of the effects of a pathological fracture by
comparing with case matched studies is required.
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